Scientific publications on lymphomas

The results and conclusions of the work conducted by the Lymphoma Research Experts ecosystem are published in leading medical journals.

Lysa 2026_End-of-induction circulating tumor DNA outperforms conventional cellular MRD for predicting early progression in follicular lymphoma: an ancillary study of the RELEVANCE randomized trial.
Claudel A, Viailly P-J, Feugier P, Rossi C, Bourcier J, Lemonnier F, Camus V, Ribrag V, Durot E, Pica GM, Nicolas-Virelizier E, Tessoulin B, Bachy E, Guidez S, Daguindau N, Sarkozy C, Xerri L, Portugues C, Trabelsi N, Morschhauser F, Delfau-Larue M-H.
Blood Cancer J 2026. Learn more
Lysa 2026_SENIOR-IPI: An easily applicable prognostic index for first-line large B-cell lymphomas patients >80 years treated with curative intent.
Dubois S, Cherblanc F, Belot A, Oberic L, Ghesquières H, Haioun C, Tilly H, Jais J-P, Jardin F.
Br J Haematol 2026. Learn more
Lysa 2026_Constructing an External Control Arm Using the French REALYSA Cohort to Replicate Outcomes of a Randomized Trial Arm in Advanced Hodgkin Lymphoma.
Febvey-Combes O, Rossi C, Kassai B, Murairi Mirimo T, Chartier L, Cherblanc F, Cugnod E, Ghesquières H, Belot A.
Clin Pharmacol Ther 2026. Learn more
Lysa 2026_Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort.
Cheminant M, Fogarty P, Carras S, Sarkozy C, Rossi C, Fornecker L, Fontanet B, Chauchet A, Leguyader-Peyrou S, Lebras L, Oberic L, Ysebaert L, Damaj G, Labouré G, Fouillet L, Guidez S, Lemonnier F, Bouabdallah K, Gastinne T, Morineau N, Amorim S, Jardin F, Abraham J, Houot R, Thieblemont C, Morschhauser F, Gressin R, Le Gouill S, Hermine O, Cherblanc F, Monnereau A, Belot A, Ghesquieres H, Tessoulin B.
Hematol Oncol 2026;44:e70264. Learn more
Lysa 2026_Outcomes of refractory and early-relapsed large B-cell lymphoma patients after first-line treatment in the prospective Real-world dAta in LYmphoma patients and Survival in Adults (REALYSA) cohort in the pre-CAR T era.
Guidez S, Belot A, Cherblanc F, Lesné B, Carras S, Thieblemont C, Bijou F, Rossi C, Fornecker LM, Dupuis J, Bouabdallah K, Fouillet L, Chauchet A, Tessoulin B, Ysebaert L, Pauc A, Cony-Makhoul P, Gressin R, Laboure G, Bonnet A, Amorim S, Fruchart C, Houot R, Pica GM, Soussain C, Dennetiere S, Leyronnas C, Lionne-Huyghe P, Ghesquières H, Sesques P.
Br J Haematol 2026. Learn more
Lysa 2026_ Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry.
Manson G, Di Blasi R, Houot R, Morschhauser F, Cartron G, Gastinne T, Blaise D, Gros F-X, Bories P, Le Bras F, Rubio M-T, Mohty M, Bay J-O, Guidez S, Castilla Llorente C, Jardin F, Durand A, Guffroy B, Loschi M, Drieu La Rochelle L, Abraham J, Chauchet A, Herbreteau L, Choquet S, Joris M, Carras S, Damaj G-L, Decroocq J, Aline T-S, Hermine O, Nicolas-Virelizier E, Gat E, Le Gouill S, Bachy E, Dulery R.
Bone Marrow Transplant 2026:1–7. Learn more
Lysa 2026_Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial.
Renaud L, Chaillol I, Galtier J, Bommier C, Tessoulin B, De Colella JMS, Lamy T, Borel C, Stamatoullas A, Gac AC, Morschhauser F, Andre M, Ghesquieres H, Traverse-Glehen A, Casasnovas O, Gastine T.
Haematologica 2026. Learn more
Lysa 2026_Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study.
Al Tabaa Y, Bailly C, Palard-Novello X, Cottereau A-S, Tordo J, Sesques P, Cartron G, Houot R, Di Blasi R, Manson G, Lesne B, Ysebaert L, Kanoun S, Van Zele E, Le Gouill S, Tessoulin B, Bodet-Milin C, Kraeber-Bodéré F, Vercellino L.
Eur J Nucl Med Mol Imaging 2026. Learn more
Lysa 2026_Interim assessment by circulating tumor DNA in primary mediastinal large B-cell lymphoma: a multicenter LYSA study.
Camus V, Krzisch D, Bruscaggin A, Lévêque E, Viennot M, Fornecker L-M, Cheminant M, Bailly S, Morschhauser F, Feugier P, Choquet S, Durot E, Carras S, Delette C, Damaj G-L, Waultier-Rascalou A, Lebreton P, Le Du K, Galtier J, Houot R, Morineau N, Laribi K, Lebras L, Oberic L, Amorim S, Bocchetta S, Viailly P-J, Rainville V, Ruminy P, Caillot M, Terzi di Bergamo L, Piffaretti D, Pirosa M-C, Salehi M, Forestieri G, Drieux F, Veresezan E-L, Traverse-Glehen A, Donzel M, Burel L, Bohers E, Lanic M-D, Penther D, Becker S, Decazes P, Tonnelet D, Draye-Carbonnier S, Tilly H, Jardin F, Rossi D, Sesques P.
Blood Adv 2026;10:4455–67. Learn more
Lysa 2026_Hemophagocytic lymphohistiocytosis-like syndrome after CD19-directed CAR T-cells for B-cell lymphoma and B-cell acute lymphoblastic leukemia: A LYSA, SFCE, and GRAALL study from the DESCAR-T registry.
Gower N, Houot R, Pizot C, Baruchel A, Dourthe M-E, Beauvais D, Gastinne T, Brisou G, Dulery R, Guidez S, Tudesq J-J, Chauchet A, Herbreteau L, Campidelli A, Bay J-O, Sesques P, Chiche E, Gros F-X, Durand A, Lubnau M, Sterin A, Di Blasi R, Marquet A, Gat E, Rabian F, Leguay T, Roth-Guépin G, Boissel N, Morschhauser F, Paillassa J.
Hemasphere 2026;10:e70425. Learn more
Lysa 2026_Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.
Gower N, Feugier P, Westin J, Schiano De Colella J-M, Tilly H, Palomba ML, Julia E, Damaj G-L, Durand A, Flinn I, Lemonnier F, Morineau N, Ysebaert L, Bartlett N, Thieblemont C, Ribrag V, Gastinne T, Dony A, Fouillet L, Guidez S, Houot R, Da Silva MG, Barnes J, Bijou F, Cartron G, Garcia-Sancho AM, Eradat H, Cheminant M, Guillermo AL, Abrisqueta P, Abraham J, Sarkozy C, Izutsu K, Crochet G, Sehn LH, Gkasiamis A, Yge ML, Chartier L, Fowler N, Xerri L, Salles G, Morschhauser F.
Blood 2026;147:3061–8. Learn more
Lysa 2026_Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.
Lazarovici J, Amorim S, Bouabdallah K, Fournier M, Guidez S, Molina L, Morschhauser F, Delapierre B, Gastinne T, Laribi K, Launay V, Slama B, Belmecheri N, Casasnovas R-O, Corby A, Durot E, Feugier P, Nicolas-Virelizie E, Sibon D, Berriolo-Riedinger A, Edeline V, Borght TV, Damotte D, Traverse-Glehen A, Ribrag V, André M
Haematologica 2026. Learn more
Lysa 2026_Prognostic Value of Combined Baseline FDG PET/CT Radiomic Parameters in Primary Mediastinal B-Cell Lymphoma.
Decazes P, Rossi C, Sesques P, Becker S, Viennot M, Mihailescu S-D, Lemonnier F, Durot E, Gower N, Willaume A, Obéric L, Paillassa J, Antier C, Renaud L, Tournilhac O, Thieblemont C, Besson C, Lebras L, Choquet S, Le Dû K, Bonnet C, Bailly S, Damaj G-L, Laribi K, Morineau N, Houot R, Chauchet A, Jardin F, Tilly H, Veresezan E-L, Drieux F, Donzel M, Traverse-Glehen A, Tonnelet D, Camus V.
Blood Adv 2026:bloodadvances.2026020168. Learn more
Lysa 2026_Brentuximab-vedotin and bendamustine for relapsed or refractory Hodgkin lymphoma: the LYSA real-world experience.
Basile G, Neuville A, Martineau D, Delapierre B, Dubois S, Noel R, Durot E, Caillet A, Labouré G, Laribi K, Gros F-X, Bernard S, Mineur A, Borel C, Chartier L, Damaj G, Bouabdallah K, Galtier J.
Haematologica 2026. Learn more
Lysa 2026_Anti-CD19 CAR T-cell therapy in relapsed/refractory T-cell/histiocyte-rich large B-cell lymphoma: insights from the French DESCAR-T registry, a LYSA study.
André A, Bourbon E, Cartron G, Morschhauser F, Fayard A, Ricard L, Di Blasi R, Chauchet A, Guidez S, Castilla-Llorente C, Brisou G, Bories P, Houot R, Cuozzo A, Gat E, Lemonnier F, Laurent C.
Haematologica 2026. Learn more
Lysa 2026_Approche méthodologique de chaînage indirect des données de la cohorte REALYSA de patients porteurs de lymphome et du SNDS
Schülé D, Guyot E, Pauc A, Poncet C, Belot A, Belhassen M, Deygas F, Bornier N, Cherblanc F, Ghesquières H.
Journal of Epidemiology and Population Health 2026;74:203252. Learn more
Lysa 2026_. Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).
Alshatti N, Lemonnier F, Bachy E, Lopez J, Llamas F, Damotte D, Burron B, Velut Y, Mauduit C, de Charette M, Roussel M, Palard X, Marabelle A, Huot R. Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).
Immunooncol Technol 2026;29:101077. Learn more
Lysa 2026_Late failure of aggressive B-cell lymphoma following CAR T-cell therapy: a LYSA study from the DESCAR-T registry.
Erbella, F, Di Blasi, R.
Blood Advances 2026. Learn more
Lysa 2026_Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy.
Ghesquières H, Drouet Y, Slager SL, Morschhauser F, Julia E, Galimberti S, Robinson D, Larson MC, Testard Q, Tesson B, Deleuze J-F, Boland A, Thomas E, Lasset C, Novak AJ, Xerri L, Luminari S, Verney A, Laurent C, Rimsza LM, Habermann TM, Federico M, Link BK, Salles G, Cerhan JR.
Blood Cancer J 2026;16:22. Learn more
Lysa 2026_Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm
G C, I C, R H, Y AT, F LB, L Y, S C, F J, Jo B, Fx G, F M, C R, T G, C T, M J, L R, C R, Ld LR, P F, A M, R O-A, K T, C L, P S.
Journal of Hematology & Oncology 2026 Learn more
Lysa 2026_Breast implants and cancer: Anaplastic large cell lymphoma in breast implants.
Bosc R, Dao TH, Haioun C.
Ann Chir Plast Esthet 2026;71:93–103. Learn more
Lysa 2026_. Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group
Sesques P, Manson G, Cartron G, Gros F-X, Morschhauser F, Castilla-Llorente C, Brisou G, Bories P, Thieblemont C, Drieu La Rochelle L, Tessoulin B, André A, Rossi C, Paillassa J, Guidez S, Capes A, Herbreteau L, Choquet S, Bay J-O, Chauchet A, Lebras L, Claves F, Abraham J, Malfuson J-V, Rubio M-T, Decroocq J, Fornecker L-M, Damaj G, Fouillet L, Joris M, Loschi M, Hermine O, Hafirassou H, Zele EV, Dupont V, Gouill SL, Houot R, Camus V.
HemaSphere 2026;10:e70356. Learn more
Lysa 2026_Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.
Sesques P, Houot R, Tabaa YA, Bras FL, Ysebaert L, Choquet S, Jardin F, Bay J-O, Gros F-X, Morschhauser F, Rossi C, Gastinne T, Thieblemont C, Joris M, Ricard L, Regny C, Rochelle LDL, Feugier P, Marcais A, Griolet S, Tarte K, Laurent C, Cartron G.
Haematologica 2026. Learn more
Lysa 2025_Outcomes and treatment patterns of patients with primary mediastinal B-cell lymphoma after CAR-T cell therapy failure: A DESCAR-T analysis
Galtier J, Sesques P, Dupont V, Bachy E, Di Blasi R, Thieblemont C, Brisou G, Gastinne T, Cartron G, Gros F-X, Morschhauser F, André A, Bay J-O, Joris M, Tanguy-Schmidt A, Demailly A, Le Gouill S, Houot R, Bouabdallah K, Camus V
Hemasphere 2025;9:e70263. Learn more